Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Chris Tran, Samedy Ouk, Nicola J. Clegg, Yu Chen, Philip A. Watson, Vivek Arora, John Wongvipat, Peter M. Smith-Jones, Dongwon Yoo, Andrew Kwon, Teresa Wasielewska, Derek Welsbie, Charlie Degui Chen, Celestia S. Higano, Tomasz (Tom) Beer, David T. Hung, Howard I. Scher, Michael E. Jung, Charles L. Sawyers

    Research output: Contribution to journalArticle

    1318 Citations (Scopus)

    Abstract

    Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.

    Original languageEnglish (US)
    Pages (from-to)787-790
    Number of pages4
    JournalScience
    Volume324
    Issue number5928
    DOIs
    StatePublished - May 8 2009

    Fingerprint

    Androgen Antagonists
    Prostatic Neoplasms
    Androgen Receptors
    Castration
    Androgens
    Nonsteroidal Anti-Androgens
    Therapeutics
    Phase II Clinical Trials
    Clinical Trials, Phase I
    Response Elements
    Prostate-Specific Antigen
    Biomarkers
    DNA
    Serum
    Pharmaceutical Preparations
    MDV 3100
    Neoplasms

    ASJC Scopus subject areas

    • General
    • Medicine(all)

    Cite this

    Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., ... Sawyers, C. L. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787-790. https://doi.org/10.1126/science.1168175

    Development of a second-generation antiandrogen for treatment of advanced prostate cancer. / Tran, Chris; Ouk, Samedy; Clegg, Nicola J.; Chen, Yu; Watson, Philip A.; Arora, Vivek; Wongvipat, John; Smith-Jones, Peter M.; Yoo, Dongwon; Kwon, Andrew; Wasielewska, Teresa; Welsbie, Derek; Chen, Charlie Degui; Higano, Celestia S.; Beer, Tomasz (Tom); Hung, David T.; Scher, Howard I.; Jung, Michael E.; Sawyers, Charles L.

    In: Science, Vol. 324, No. 5928, 08.05.2009, p. 787-790.

    Research output: Contribution to journalArticle

    Tran, C, Ouk, S, Clegg, NJ, Chen, Y, Watson, PA, Arora, V, Wongvipat, J, Smith-Jones, PM, Yoo, D, Kwon, A, Wasielewska, T, Welsbie, D, Chen, CD, Higano, CS, Beer, TT, Hung, DT, Scher, HI, Jung, ME & Sawyers, CL 2009, 'Development of a second-generation antiandrogen for treatment of advanced prostate cancer', Science, vol. 324, no. 5928, pp. 787-790. https://doi.org/10.1126/science.1168175
    Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-790. https://doi.org/10.1126/science.1168175
    Tran, Chris ; Ouk, Samedy ; Clegg, Nicola J. ; Chen, Yu ; Watson, Philip A. ; Arora, Vivek ; Wongvipat, John ; Smith-Jones, Peter M. ; Yoo, Dongwon ; Kwon, Andrew ; Wasielewska, Teresa ; Welsbie, Derek ; Chen, Charlie Degui ; Higano, Celestia S. ; Beer, Tomasz (Tom) ; Hung, David T. ; Scher, Howard I. ; Jung, Michael E. ; Sawyers, Charles L. / Development of a second-generation antiandrogen for treatment of advanced prostate cancer. In: Science. 2009 ; Vol. 324, No. 5928. pp. 787-790.
    @article{1e3dddf39edc4ecf9bf73096d82c62d9,
    title = "Development of a second-generation antiandrogen for treatment of advanced prostate cancer",
    abstract = "Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43{\%}) showed sustained declines (by >50{\%}) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.",
    author = "Chris Tran and Samedy Ouk and Clegg, {Nicola J.} and Yu Chen and Watson, {Philip A.} and Vivek Arora and John Wongvipat and Smith-Jones, {Peter M.} and Dongwon Yoo and Andrew Kwon and Teresa Wasielewska and Derek Welsbie and Chen, {Charlie Degui} and Higano, {Celestia S.} and Beer, {Tomasz (Tom)} and Hung, {David T.} and Scher, {Howard I.} and Jung, {Michael E.} and Sawyers, {Charles L.}",
    year = "2009",
    month = "5",
    day = "8",
    doi = "10.1126/science.1168175",
    language = "English (US)",
    volume = "324",
    pages = "787--790",
    journal = "Science",
    issn = "0036-8075",
    publisher = "American Association for the Advancement of Science",
    number = "5928",

    }

    TY - JOUR

    T1 - Development of a second-generation antiandrogen for treatment of advanced prostate cancer

    AU - Tran, Chris

    AU - Ouk, Samedy

    AU - Clegg, Nicola J.

    AU - Chen, Yu

    AU - Watson, Philip A.

    AU - Arora, Vivek

    AU - Wongvipat, John

    AU - Smith-Jones, Peter M.

    AU - Yoo, Dongwon

    AU - Kwon, Andrew

    AU - Wasielewska, Teresa

    AU - Welsbie, Derek

    AU - Chen, Charlie Degui

    AU - Higano, Celestia S.

    AU - Beer, Tomasz (Tom)

    AU - Hung, David T.

    AU - Scher, Howard I.

    AU - Jung, Michael E.

    AU - Sawyers, Charles L.

    PY - 2009/5/8

    Y1 - 2009/5/8

    N2 - Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.

    AB - Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD162 and MDV3100, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and MDV3100 are orally available and induce tumor regression in mouse models of castration-resistant human prostate cancer. Of the first 30 patients treated with MDV3100 in a Phase I/II clinical trial, 13 of 30 (43%) showed sustained declines (by >50%) in serum concentrations of prostate-specific antigen, a biomarker of prostate cancer. These compounds thus appear to be promising candidates for treatment of advanced prostate cancer.

    UR - http://www.scopus.com/inward/record.url?scp=65649090203&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=65649090203&partnerID=8YFLogxK

    U2 - 10.1126/science.1168175

    DO - 10.1126/science.1168175

    M3 - Article

    C2 - 19359544

    AN - SCOPUS:65649090203

    VL - 324

    SP - 787

    EP - 790

    JO - Science

    JF - Science

    SN - 0036-8075

    IS - 5928

    ER -